{"preliminary_commentary":{"by_channel":{"x_thread":81,"youtube":70,"podcast":69,"bluesky_thread":1,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04482309\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-29T05:47:14.328Z","note":"Automated from the 40 newest of 222 indexed sources (Apr 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"- Whether HER2 testing variability changes treatment eligibility or expected benefit\n- How HER2 expression level should guide treatment selection\n- Whether the ovarian cancer evidence is sufficient to guide treatment decisions\n- How interstitial lung disease risk should influence treatment and retreatment decisions\n\nAlso discussed: first-line development."},"drugs_tested":[["trastuzumab deruxtecan"]],"indication":"HER2-expressing solid tumors","name":"DESTINY-PanTumor02","nct_id":"NCT04482309","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destiny-pantumor02-nct04482309. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DPT02","arms":[{"description":"Biliary tract cancer","label":"Part 1 Cohort 1","type":"EXPERIMENTAL"},{"description":"Bladder cancer","label":"Part 1 Cohort 2","type":"EXPERIMENTAL"},{"description":"Cervical cancer","label":"Part 1 Cohort 3","type":"EXPERIMENTAL"},{"description":"Endometrial cancer","label":"Part 1 Cohort 4","type":"EXPERIMENTAL"},{"description":"Ovarian cancer","label":"Part 1 Cohort 5","type":"EXPERIMENTAL"},{"description":"Pancreatic cancer","label":"Part 1 Cohort 6","type":"EXPERIMENTAL"},{"description":"Rare tumors","label":"Part 1 Cohort 7","type":"EXPERIMENTAL"},{"description":"Any tumor type that is HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer)","label":"Part 2 Cohort A","type":"EXPERIMENTAL"},{"description":"Any tumor type that is HER2 IHC 2+/ISH+ (excluding breast, gastric cancer, and colorectal cancer)","label":"Part 2 Cohort B","type":"EXPERIMENTAL"},{"description":"HER2 IHC 2+ or 1+ endometrial cancer","label":"Part 2 Cohort C","type":"EXPERIMENTAL"},{"description":"HER2 IHC 2+ or 1+ ovarian cancer","label":"Part 2 Cohort D","type":"EXPERIMENTAL"},{"description":"HER2 IHC 2+ or 1+ cervical cancer","label":"Part 2 Cohort E","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo Co., Ltd."],"completion_date":{"date":"2027-03-23","type":"ESTIMATED"},"conditions":["Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer","Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer"],"enrollment":{"count":477,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Trastuzumab deruxtecan","otherNames":["DS-8201a","T-DXd"],"type":"DRUG"}],"last_update":"2026-07-10","lead_sponsor":"AstraZeneca","official_title":"A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-03-23","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"An average of approximately 6 months"}],"references":[{"citation":"Lee JY, Oaknin A, Manso L, Gonzalez-Martin A, Lugowska I, Lorusso D, Banerjee S, Liao JB, Lu CH, Prasongsook N, Melichar B, Anoka C, Jung L, Michelini F, Puvvada S, Meric-Bernstam F, Makker V. Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses. J Gynecol Oncol. 2026 May;37(3):e65. doi: 10.3802/jgo.2026.37.e65. Epub 2026 May 6.","pmid":"42135959","type":"DERIVED"},{"citation":"Oaknin A, Lee JY, Makker V, Oh DY, Banerjee S, Gonzalez-Martin A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Puvvada S, Smith A, Meric-Bernstam F. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Adv Ther. 2024 Nov;41(11):4125-4139. doi: 10.1007/s12325-024-02975-x. Epub 2024 Sep 11.","pmid":"39261417","type":"DERIVED"},{"citation":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonzalez-Martin A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23.","pmid":"37870536","type":"DERIVED"}],"start_date":{"date":"2020-08-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","url":"https://clinicaltrials.gov/study/NCT04482309"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destiny-pantumor02-nct04482309"}